An observational study in Polycystic Ovary Syndrome, sponsored by Hospital Clinic of Barcelona. Status unknown at 1 site in Spain. Open to female participants aged 16 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-20.
Sponsored by Hospital Clinic of Barcelona · Observational
Among 14 studies in Polycystic Ovary Syndrome with a site in Spain — 3 open to participants now, 3 under way, none of them phase 3. Polycystic Ovary Syndrome · Spain.
Among the 14 studies in Polycystic Ovary Syndrome with a site in Spain, this one is the only one that started in 2018, is one of 4 observational ones, and was the 6th registered.
956 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →3 of the 14 studies in Polycystic Ovary Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Celia Bañuls · Sites in Spain
Fundació Sant Joan de Déu · Sites in Spain, Austria, Denmark and 3 more countries
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 118 across 223 observational studies indexed under Polycystic Ovary Syndrome.
Median enrollment 50 across the 10 interventional studies, 60 across the 4 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 55 are open to participants now.
Hospital Clinic of Barcelona has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Polycystic Ovary Syndrome with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06551285Celia BañulsStudy of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome. | 2026-12-31 |
Among the 14 studies in Polycystic Ovary Syndrome with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A prospective assessment of psychological characteristics, quality of life and sexuality in naïve patients.
This project with PCOS patients include an assessment of quality of life and sexuality in naïve patients.
Hypothesizing that PCOS women would show higher rates of psychological alterations, this study is aimed to investigate the association between polycystic ovary syndrome (PCOS) and psychological disturbances, including anger and to analyze whether the biochemical/phenotypical features of PCOS may play a role in the type and severity of psychological disorders.
The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PCOS patients without gestational desire who met the following criteria
Exclusion Criteria:
The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting \>35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded
Diagnostic Test: SF-36 (Short Form Health Survey)
The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
Diagnostic Test: SF-36 (Short Form Health Survey)
Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism). State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health. Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score.
Also known as: Female Sexual Function Index; Symptom Checklist-90-R; State-Trait-Anger-Expression-Inventory
Quality of Life
results of SF-36
Time frame: january 9th 2018-january 9th 2019
Sexuality
Results of FSFI
Time frame: january 9th 2018-january 9th 2019
Psychological distress
Results of Symptom Checklist-90-Revision (SCL-90-R)
Time frame: january 9th 2018-january 9th 2019
Anger and aggressiveness
results of State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2)
Time frame: january 9th 2018-january 9th 2019
Biochemical markers
Results of blood tests including biochemistry and hormones analysis
Time frame: january 9th 2018-january 9th 2019
Phenotipical traits
Record of hirsutism, acne, alopecia, and other hyperandrogenic symptoms
Time frame: january 9th 2018-january 9th 2019
Plan to share: No
Start is estimated for Jan 2018; primary completion for Jan 2019, 12 months later.
Of 71 non-industry observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 6 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Clinic of Barcelona →